The trajectory of the erectile dysfunction drug presents a challenging picture for investors. While the initial release generated significant profits, the lapse of its patent opened the floodgates to cheaper versions, https://fanniekrms851084.blogsvila.com/42142019/sildenafil-and-pharma-a-risky-investment